Please login to the form below

Not currently logged in

drug pricing

This page shows the latest drug pricing news and features for those working in and with pharma, biotech and healthcare.

Novartis follows Pfizer and freezes US prices this year

Novartis follows Pfizer and freezes US prices this year

s drug pricing policy – although Narasimhan said he thinks this matter has now been resolved. ... However, sales at Sandoz were flat overall as pricing pressure pegged back small-molecule generics in the US.

Latest news

More from news
Approximately 55 fully matching, plus 192 partially matching documents found.

Latest Intelligence

  • Patient outcomes in practice: delivering value that transforms lives Patient outcomes in practice: delivering value that transforms lives

    Providers, payers and manufacturers all have a role in achieving value, with increasing ethical pressure on drug pricing and resultant innovative, outcomes-based pricing models.

  • Drug pricing

    Healthcare terms - Drug pricing.

  • Healthcare Glossary

    Double-blind trial. A clinical trial design in which neither the participating individuals nor the study staff know which participants are receiving the experimental drug and which are receiving either placebo ... Double-blind trials are thought to

  • Risky business for pharma Risky business for pharma

    Chan Lee, North America general counsel, Sanofi, explained: “Drug pricing is a significant risk in our industry, particularly in the US.”Lee also cited “scrutiny of manufacturer interactions with payers, patients, ... PD Villareal, senior vice

  • The gold standard of scientific evidence The gold standard of scientific evidence

    The FDA uses RWE to monitor drug safety as part of the Sentinel project. ... Additionally, RWE is being used to inform. creative drug pricing. When seeking coverage for Kymriah, a new CAR-T therapy, Novartis has an agreement with the Centers for Medicaid

More from intelligence
Approximately 7 fully matching, plus 28 partially matching documents found.

Latest appointments

  • Pfizer’s Emms takes up ABPI presidency Pfizer’s Emms takes up ABPI presidency

    Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the

  • Bayer's Martin Hesse moves to Daiichi Sankyo Europe

    Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge. “

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A roadmap to strategic drug pricing

    A roadmap to strategic drug pricing. The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. ... A roadmap to strategic drug pricing.

  • Pricing's Point Man

    Pricing's Point Man. In the wake of the publication of the second edition of 'The Price of Global Health', Ed Schoonveld talks to William Looney.

  • EY Life Sciences

    A roadmap to strategic drug pricing. ... In 2016, a renewed focus on value-based drug pricing, staunch competition across key therapeutic battlegrounds and consolidated payer clout may exacerbate existing growth gaps, resulting in a continued feverish

  • Ed Schoonveld - new article

    Ed Schoonveld - new article. Following the publication of the new edition of The Price of Global Health, Ed Schoonveld writes about the industry's need for new drug pricing model. ... Does the drug industry need a new pricing model? Read Ed Schoonveld's

  • The Price of Global Health

    Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation.

More from PMHub
Approximately 4 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....